Form 4: CVS Health Executive Tilak Mandadi Reports Stock Transactions

CVS Health's EVP, Chief DDAT Officer, Tilak Mandadi, reported the acquisition of restricted stock units and the disposal of common stock.

Summary

• Tilak Mandadi, an EVP at CVS Health, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On November 30, 2024, Mandadi acquired 50,125 restricted stock units (RSUs) at a price of $59.85 per unit.
• These RSUs will vest in three equal installments starting November 30, 2025.
• On the same day, Mandadi disposed of 40,414 shares of common stock.
• Mandadi also holds stock options for 96,496 shares exercisable starting April 1, 2024, and 67,920 shares exercisable starting April 1, 2025.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no indication of positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The vesting schedule of the restricted stock units is typical for executive compensation packages.
• The stock option exercise prices and vesting schedules are within the range of what is seen in similar companies.

Stakeholder Impact

• The stock transactions may have a minor impact on the overall share price, but are not expected to be significant.
• The vesting of restricted stock units aligns executive interests with long-term company performance.

Key Dates

Keywords

CVS Health, Tilak Mandadi, stock transaction, Form 4, restricted stock units, stock options, beneficial ownership